The benefits of removing senescent cells should be assessed beyond lifespan, says Aubrey de Grey
The benefits of removing senescent cells should be assessed beyond lifespan, says Aubrey de Grey
On November 8, aging researcher Aubrey de Grey joined the debate over a critical essay by gerontologist Richard Miller. The discussion concerned senolytics, agents that remove cells showing signs of cellular senescence: these cells persistently stop dividing and change the mix of substances they release into the surrounding tissue.
In a critical essay on aging, Miller said that the finding that removing these cells extended mouse lifespan had not been replicated. A reader asked de Grey whether he considered senolytics a scam. De Grey acknowledged the lack of replication and supported Miller’s call for more precise distinctions between cell states. His objection concerned the conclusion about benefits:
“The absence of lifespan extension is not evidence against a benefit.”
In the 2004 paper he cited, de Grey examined a scenario in which an intervention slows one harmful process while others continue to limit lifespan.
The 2016 experiment under discussion tested the hypothesis that accumulating cells with these features impair organ function and that removing them benefits normally aging mice. In the INK-ATTAC genetic model, researchers engineered an additional cell-death mechanism into the cells. This mechanism was controlled by a fragment of the DNA region that regulates the activity of the p16 gene. This gene helps stop cell division, and its increased activity is one marker of cellular senescence. Cells with this marker are called p16-positive cells. Administering a compound triggered the death of some of these cells.
The authors reported an increase in median lifespan, the age to which half the mice survive, compared with the control groups. The animals also retained better function in several organs, including the kidneys. The authors thanked Miller for helping to design and interpret the lifespan study. In the same study, cell removal slowed skin wound healing when treatment continued during recovery. When administration of the compound was paused during healing, the mice retained their ability to heal wounds. De Grey clarified:
“Some p16-positive cells may be beneficial even if others are harmful.”
Later in the discussion, a reader cited a January 2025 episode of physician Peter Attia’s podcast featuring Miller. Miller said he had tried seven times to confirm cell removal in the INK-ATTAC genetic model and had detected none on any attempt. Coded tissue samples were sent to aging researcher Judith Campisi’s laboratory. Researchers there measured markers of cellular senescence without knowing which mice had received the compound. According to Miller, this analysis also found no evidence of cell removal. He wanted to confirm cell removal before beginning an expensive lifespan study.
- https://t.me/UkhvatNews/4758
- https://x.com/aubreydegrey/status/2119251618961240240
- https://web.archive.org/web/20100613024843id_/http://sens.org/files/pdf/m17prep.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4845101/
- https://x.com/aubreydegrey/status/2119252746499207644
- https://www.youtube.com/watch?v=NU98SXBCjz4&t=7270s